- was
established in 1973 and
merged with
Synthélabo in 1999 to form Sanofi-
Synthélabo. In 2004, Sanofi-
Synthélabo merged with
Aventis and
renamed to Sanofi-Aventis...
- Rhône-Poulenc S.A. in 1999. With the new company's 2004
merger with Sanofi-
Synthélabo, it
became a
subsidiary of the
resulting Sanofi-Aventis pharmaceuticals...
-
purchased Synthélabo in 1973 to
pursue its
ambitions in the
pharmaceutical field.
Synthélabo merged with
Sanofi in 1999 to
become Sanofi-
Synthélabo. Sanofi-Synthélabo...
-
introduced the drug
Primperan in 1964.
Laboratoires Delagrange was
acquired by
Synthelabo in 1991
which eventually became part of Sanofi. A.H.
Robins introduced...
- Rhône-Poulenc to
become Aventis in 1999 and in 2004
Aventis merged with Sanofi-
Synthélabo to
become Sanofi-Aventis. In 2005,
around 22,000
people worked at Industriepark...
- used in
Europe starting in 1988 and was
brought to
market there by
Synthelabo.
Synthelabo and
Searle collaborated to
bring it to
market in the US, and it...
-
Hoechst AG to form Aventis. In 2004,
Aventis went on to
merge with Sanofi-
Synthélabo forming Sanofi-Aventis, the third-largest
pharmaceutical company in the...
-
metoclopramide and
later to sulpiride.
Laboratoires Delagrange was
acquired by
Synthelabo in 1991
which eventually became part of Sanofi.
Sulpiride is marketed...
-
Apotex Inc v Sanofi-
Synthelabo Canada Inc, [2008] 3 S.C.R. 265, is a
leading Supreme Court of
Canada decision on the
novelty and non-obviousness requirements...
- 1999, two
French pharmaceutical companies,
Sanofi and
Synthélabo,
merged to form Sanofi-
Synthélabo. Soon
after the merger, the new
company divested several...
